These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20845054)

  • 21. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
    BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Beck J; Bellmunt J; Escudier B
    Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Granulocyte colony stimulating factor (G-CSF) producing renal cell carcinoma].
    Sato T; Yamauchi N; Kobayashi D; Sato Y; Mochizuki C; Hori C; Watanabe N; Niitsu Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1189-93. PubMed ID: 9423336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Zołnierek J; Nurzyński P; Langiewicz P; Oborska S; Waśko-Grabowska A; Kuszatal E; Obrocka B; Szczylik C
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):371-8. PubMed ID: 19711099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G; Autorino R
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
    Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
    Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
    Shinsako K; Mizuno T; Terada T; Watanabe J; Kamba T; Nakamura E; Ogawa O; Inui K
    Int J Clin Oncol; 2010 Oct; 15(5):512-4. PubMed ID: 20340037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
    Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
    Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of targeted therapies for renal cell cancer].
    Merseburger AS; Kuczyk MA
    Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
    Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor].
    Saito H; Oyama K; Fushida S; Tsukada T; Okamoto K; Nakanuma N; Kinoshita J; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):799-802. PubMed ID: 23863662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
    Negrier S; Jäger E; Porta C; McDermott D; Moore M; Bellmunt J; Anderson S; Cihon F; Lewis J; Escudier B; Bukowski R
    Med Oncol; 2010 Sep; 27(3):899-906. PubMed ID: 19757215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
    J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
    Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.